FIC, oral, QD C5aR antagonist FDA-approved as adjunctive treatment for AAV discovery not disclosed avacopan (CCX-168, TAVNEOS) ChemoCentryx, San Carlos, CA; Amgen Inc., Thousand Oaks, CA